{"version":"1.0","type":"link","title":"Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.","author_name":"Urman A 외","author_url":"https://prs-insight.online/author/Urman%20A","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/149262","thumbnail_width":1200,"thumbnail_height":630}